Sethera Therapeutics Bolsters Leadership with Biotech Luminary Dr. Robert Langer and Military Strategist Brigadier General Larry Lunt

Sethera Therapeutics has made two strategic leadership appointments that could signal a transformative period for the biopharmaceutical company's peptide therapeutics platform. Dr. Robert Langer, a pioneering MIT scientist and Moderna co-founder, will head the Scientific Advisory Board, while Brigadier General Larry V. Lunt will join the Board of Directors.

Dr. Langer brings unprecedented scientific credibility to Sethera, with an academic profile that includes over 1,500 publications, more than 443,000 citations, and a record-breaking h-index of 330. His groundbreaking work in drug delivery systems and tissue engineering, including contributions to the COVID-19 vaccine, positions him as a critical strategic asset for the company's research and development efforts.

Brigadier General Lunt complements Langer's scientific expertise with extensive leadership experience from his 36-year military career. His background in complex organizational management and strategic vision is expected to be crucial as Sethera navigates the competitive biotechnology landscape.

The appointments underscore Sethera's commitment to developing advanced peptide-based therapies. The company's platform technology aims to create enzymatically-altered peptides with enhanced efficacy, safety, and delivery mechanisms across multiple therapeutic areas.

CEO Karsten Eastman emphasized the significance of these appointments, noting that Dr. Langer and Brigadier General Lunt will be instrumental in advancing the company's mission to transform therapeutic screening and development.

Brig. Gen. Lunt highlighted the broader implications of Sethera's work, suggesting that their precision-targeted therapeutics could have impacts beyond healthcare, potentially influencing biodefense and other critical sectors.

With these leadership additions, Sethera Therapeutics appears positioned to make substantial contributions to the field of peptide therapeutics, potentially revolutionizing approaches to treating a wide range of diseases.